SCHEMBL3721640

SCHEMBL3721640

FC(F)(F)c1cc(Br)ccc1-c1cc(CCl)on1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.39
KDM1A O60341 2/20 0.35
NPFFR1 Q9GZQ6 1/20 0.35
NPFFR2 Q9Y5X5 1/20 0.35
NOTUM Q6P988 5/20 0.33
CACNA1G O43497 2/20 0.33
MAOB P27338 2/20 0.32
MAOA P21397 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CRHR1 P34998 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542216 0.86 KCNH2 (0.42) KCNH2CACNA1GNPC1RAB9A
SCHEMBL1220445 0.84 KCNH2 (0.51) KCNH2CACNA1GMAOBMAOA
SCHEMBL1437522 0.84 P2RY14 (0.38) KCNH2KDM1ANPFFR1NPFFR2NOTUM
SCHEMBL3721862 0.83 CACNA1G (0.42) KCNH2CACNA1GMAOBMAOANPC1
SCHEMBL1220435 0.80 MAPT (0.41) NPC1RAB9ACRHR1CYP1A2MAPT
SCHEMBL3723404 0.80 GPR3 (0.37) KCNH2CACNA1GNPC1RAB9AS1PR1
SCHEMBL3724820 0.78 LMNA (0.41) KCNH2NPC1RAB9AMAPTHTT
SCHEMBL1220433 0.77 ALDH1A1 (0.36) KCNH2CACNA1GNPC1RAB9AS1PR1
SCHEMBL3728740 0.76 L3MBTL1 (0.36) KCNH2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL3718958 0.76 ACACB (0.39) KCNH2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081145-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLAXOSMITHKLINE LLC (US) 2010-07-15 WO disclosed
US-20090197880-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197880-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HAVCR2, SARS1, RPL35 KCNH2 2037/4885KDM1A 3691/4885NPFFR1 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.